Julien Fleurence

597 total citations
9 papers, 333 citations indexed

About

Julien Fleurence is a scholar working on Molecular Biology, Neurology and Immunology. According to data from OpenAlex, Julien Fleurence has authored 9 papers receiving a total of 333 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Neurology and 4 papers in Immunology. Recurrent topics in Julien Fleurence's work include Neuroblastoma Research and Treatments (4 papers), Glycosylation and Glycoproteins Research (3 papers) and CAR-T cell therapy research (2 papers). Julien Fleurence is often cited by papers focused on Neuroblastoma Research and Treatments (4 papers), Glycosylation and Glycoproteins Research (3 papers) and CAR-T cell therapy research (2 papers). Julien Fleurence collaborates with scholars based in France, United States and Mexico. Julien Fleurence's co-authors include Andras Heczey, Rahamthulla S. Shaik, Amy N. Courtney, Thao P. Nguyen, Leonid S. Metelitsa, Maksim Mamonkin, Linjie Guo, Purva Rathi, Julien Balzeau and Meng‐Fen Wu and has published in prestigious journals such as PLoS ONE, International Journal of Cancer and Oncotarget.

In The Last Decade

Julien Fleurence

9 papers receiving 330 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julien Fleurence France	7	217	144	140	58	52	9	333
Annelisa M. Cornel Netherlands	9	245 1.1×	164 1.1×	229 1.6×	27 0.5×	37 0.7×	16	439
Amirhossein Mardi Iran	11	190 0.9×	164 1.1×	129 0.9×	51 0.9×	62 1.2×	30	411
Shahrokh Abdolahi Iran	7	156 0.7×	95 0.7×	75 0.5×	55 0.9×	19 0.4×	13	311
Stefan Peinert Australia	11	254 1.2×	170 1.2×	108 0.8×	32 0.6×	86 1.7×	21	357
Valeria Leuci Italy	14	405 1.9×	127 0.9×	347 2.5×	41 0.7×	66 1.3×	27	542
Anat Globerson Levin Israel	11	226 1.0×	183 1.3×	135 1.0×	104 1.8×	45 0.9×	20	370
Ying Gong China	8	266 1.2×	130 0.9×	280 2.0×	42 0.7×	44 0.8×	25	443
Maureen Loudovaris United States	11	145 0.7×	147 1.0×	210 1.5×	15 0.3×	29 0.6×	15	406
Michelle L. Swearingen United States	7	335 1.5×	95 0.7×	346 2.5×	29 0.5×	36 0.7×	10	473

Countries citing papers authored by Julien Fleurence

Since Specialization

Citations

This map shows the geographic impact of Julien Fleurence's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julien Fleurence with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julien Fleurence more than expected).

Fields of papers citing papers by Julien Fleurence

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julien Fleurence. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julien Fleurence. The network helps show where Julien Fleurence may publish in the future.

Co-authorship network of co-authors of Julien Fleurence

This figure shows the co-authorship network connecting the top 25 collaborators of Julien Fleurence. A scholar is included among the top collaborators of Julien Fleurence based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julien Fleurence. Julien Fleurence is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Rathi, Purva, Linjie Guo, Amy N. Courtney, et al.. (2020). Glypican-3–Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. Cancer Immunology Research. 8(3). 309–320. 193 indexed citations

2.

Fleurence, Julien, Sophie Fougeray, Émilie Pinault, et al.. (2019). Impairing temozolomide resistance driven by glioma stem‐like cells with adjuvant immunotherapy targeting O‐acetyl GD2 ganglioside. International Journal of Cancer. 146(2). 424–438. 25 indexed citations

3.

Fleurence, Julien, et al.. (2019). Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation. Journal of Visualized Experiments. 3 indexed citations

4.

Fleurence, Julien, et al.. (2019). Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation. Journal of Visualized Experiments. 2 indexed citations

5.

Fougeray, Sophie, Ali El Roz, Julien Fleurence, et al.. (2017). Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside. OncoImmunology. 7(1). e1373232–e1373232. 11 indexed citations

6.

Fleurence, Julien, Sophie Fougeray, Denis Cochonneau, et al.. (2017). TargetingO-Acetyl-GD2 Ganglioside for Cancer Immunotherapy. Journal of Immunology Research. 2017. 1–16. 30 indexed citations

7.

Fleurence, Julien, Denis Cochonneau, Sophie Fougeray, et al.. (2016). Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside. Oncotarget. 7(27). 41172–41185. 43 indexed citations

8.

Birklé, Stéphane, Tanguy Chaumette, Marie‐Hélène Gaugler, et al.. (2013). Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting. OncoImmunology. 2(4). e23700–e23700. 6 indexed citations

9.

Chaumette, Tanguy, Marie‐Hélène Gaugler, Denis Cochonneau, et al.. (2012). Anti-Gb3 Monoclonal Antibody Inhibits Angiogenesis and Tumor Development. PLoS ONE. 7(11). e45423–e45423. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact